Eli Lilly opposes push to pass Trump's drug pricing deals into law, CEO says

NoodlesOrTokens · 2026-04-01T18:23:57+00:00

Eli Lilly's CEO, David Ricks, voiced opposition to the White House's plan for "most favored nation" drug pricing, arguing it could harm future drug innovation and the U.S. pharmaceutical industry. He expressed concerns about potential congressional changes to the policy.

NoodlesOrTokens

2026-04-01 18:23:57

Abstract generation in progress

In this article

Follow your favorite stocksCREATE FREE ACCOUNT

David Ricks, CEO of Eli Lilly, speaks in the Oval Office during an event about weight-loss drugs at the White House in Washington, DC on Nov. 6, 2025.

Andrew Caballero-Reynolds | AFP | Getty Images

Eli Lilly opposes the White House’s push to codify “most favored nation” drug pricing into law, CEO Dave Ricks said in an interview with CNBC.

Lilly is one of more than a dozen drugmakers that signed deals with the Trump administration last year agreeing to charge similar prices for prescription drugs in the U.S. as other wealthy nations. President Donald Trump has long complained that Americans pay high prices to subsidize low prices for medicine in the rest of the world.

The pharmaceutical industry thought the agreements would pacify those concerns and thwart attempts to make “most favored nation” pricing law. But the White House in recent months has pushed Congress to codify elements of the deals. The draft text hasn’t been shared publicly, though the administration has said it’s trying to get pharmaceutical companies back the effort.

watch now

VIDEO22:2422:24

Eli Lilly CEO: Our pill supply can ‘reach the planet’

News Videos

Lilly doesn’t support it, Ricks said.

“When you throw it into the congressional process, what goes in is not what’s going to come out,” Ricks said. “And I think we see a lot of people who would rather reduce prices today and not worry about whether we have any new medicines tomorrow, not worry about whether America will have a robust drug industry and we’ll be able to do research in this country. And I worry about those things, so I don’t think that’s a great idea, and we’ve been pretty clear with the administration and the congressional leaders about that.”

Ricks said he thinks the Trump administration and leadership on the Hill are listening to the company’s concerns, but he said Lilly will use “all the tools we have to combat bad policy, and we think it would be bad policy.”

Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes